DOXIL when combined with Withaferin A (WFA) targets ALDH1 positive cancer stem cells in ovarian cancer.

@article{Kakar2016DOXILWC,
  title={DOXIL when combined with Withaferin A (WFA) targets ALDH1 positive cancer stem cells in ovarian cancer.},
  author={Sham S. Kakar and Christopher A. Worth and Zhenglong Wang and Kelsey Carter and Mariusz Z Ratajczak and Pranesh M Gunjal},
  journal={Journal of cancer stem cell research},
  year={2016},
  volume={4}
}
Ovarian cancer is a highly aggressive and deadly disease. Currently, the treatment for ovarian cancer entails cytoreductive surgery followed by chemotherapy, mainly cisplatin or carboplatin combined with paclitaxel. Although this regimen is initially effective in a high percentage of cases, unfortunately, after few months of initial treatment, tumor relapse occurs due to platinum-resistance. DOXIL (liposomal preparation of doxorubicin) is a choice of drug for recurrent ovarian cancer. However… CONTINUE READING